HomeInsightsStock Comparison

Morepen Laboratories Ltd vs Nectar Lifescience Ltd Stock Comparison

Morepen Laboratories Ltd vs Nectar Lifescience Ltd Stock Comparison

Last Updated on: May 05, 2025

Key Highlights

  • The Latest Trading Price of Morepen Laboratories Ltd is ₹ 59.9 as of 05 May 09:48.
  • The P/E Ratio of Morepen Laboratories Ltd changed from 12.7 on March 2020 to 22.4 on March 2024 . This represents a CAGR of 12.02% over 5 yearsThe P/E Ratio of Nectar Lifescience Ltd changed from 7 on March 2020 to 136.9 on March 2024 . This represents a CAGR of 81.24% over 5 years.
  • The Market Cap of Morepen Laboratories Ltd changed from ₹ 429.13 crore on March 2020 to ₹ 2149 crore on March 2024 . This represents a CAGR of 38.03% over 5 yearsThe Market Cap of Nectar Lifescience Ltd changed from ₹ 221.79 crore on March 2020 to ₹ 675.25 crore on March 2024 . This represents a CAGR of 24.94% over 5 years.
  • The revenue of Morepen Laboratories Ltd for the Dec '24 is ₹ 458.12 crore as compare to the Sep '24 revenue of ₹ 442.71 crore. This represent the growth of 3.48% The revenue of Nectar Lifescience Ltd for the Dec '24 is ₹ 455.56 crore as compare to the Sep '24 revenue of ₹ 428.79 crore. This represent the growth of 6.24%.
  • The ebitda of Morepen Laboratories Ltd for the Dec '24 is ₹ 40.85 crore as compare to the Sep '24 ebitda of ₹ 49.06 crore. This represent the decline of -16.73% The ebitda of Nectar Lifescience Ltd for the Dec '24 is ₹ 45.28 crore as compare to the Sep '24 ebitda of ₹ 44.02 crore. This represent the growth of 2.86%.
  • The net profit of Morepen Laboratories Ltd changed from ₹ 14.63 crore to ₹ 26.69 crore over 7 quarters. This represents a CAGR of 40.99% The net profit of Nectar Lifescience Ltd changed from ₹ 1.82 crore to ₹ 7.84 crore over 7 quarters. This represents a CAGR of 130.37% .
  • The Dividend Payout of Morepen Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Nectar Lifescience Ltd changed from 3.73 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Nectar Lifescience Ltd

  • Nectar Lifescience Limited was incorporated on June 27, 1995 with the name 'Surya Medicare Limited'.
  • On March 26, 2004, Company changed their name from 'Surya Medicare Limited' to 'Nectar Lifescience Limited'.
  • NECLIFE is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products.
  • It is a global pharmaceutical company specializing in Cephalosporins.
  • Nectar excels in Cephalosporin APIs production with certified facilities meeting global standards.

Morepen Laboratories Ltd News Hub

News

Morepen receives CDSCO nod to conduct BE studies for Resmetirom

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drug...

Read more

29 Apr 2025 09:07

News

Morepen Laboratories launches four new products for domestic market

Morepen Laboratories announced the launch of four new products'Ticapen, UdoFix, LycoMore, ...

Read more

24 Apr 2025 16:13

News

Morepen Laboratories plans to add 1,000 medical representatives

Morepen Laboratories today announced a bold expansion plan aimed at deepening its connect ...

Read more

11 Apr 2025 09:16

News

Morepen Lab jumps on plans to expand salesforce

The move is aimed at strengthening Morepen's connect with doctors, pharmacies, patients, a...

Read more

11 Apr 2025 12:05

News

Morepen Laboratories receives China NMPA approval for Loratadine

Morepen Laboratories has received approval from the Center for Drug Evaluation (CDE) of th...

Read more

01 Apr 2025 09:08

News

Morepen Lab gains after receiving Loratadine approval for export to China

Loratadine is used to temporarily relieve the symptoms of hay fever (allergy to pollen, du...

Read more

01 Apr 2025 11:04

Nectar Lifescience Ltd News Hub

News

Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities

In a regulatory filing made after market hours yesterday, the company stated that its API ...

Read more

11 Mar 2025 12:24

News

Nectar Lifescience announces board meeting date

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 31 Janu...

Read more

24 Jan 2025 16:30

News

Nectar Lifescience schedules board meeting

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 Nove...

Read more

04 Nov 2024 16:03

News

Nectar Lifescience to conduct AGM

Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be ...

Read more

20 Aug 2024 16:12

News

Nectar Lifescience to convene AGM

Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be ...

Read more

20 Aug 2024 10:47

News

Nectar Lifescience to conduct board meeting

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 Augu...

Read more

06 Aug 2024 16:18

SWOT Analysis Of Nectar Lifescience Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Nectar Lifescience Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Morepen Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Morepen Laboratories Ltd and Nectar Lifescience Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Nectar Lifescience Ltd?

Market cap of Morepen Laboratories Ltd is 3,246 Cr while Market cap of Nectar Lifescience Ltd is 489 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Nectar Lifescience Ltd?

The stock performance of Morepen Laboratories Ltd and Nectar Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Nectar Lifescience Ltd?

As of May 5, 2025, the Morepen Laboratories Ltd stock price is INR ₹59.25. On the other hand, Nectar Lifescience Ltd stock price is INR ₹21.81.

How do dividend payouts of Morepen Laboratories Ltd and Nectar Lifescience Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Nectar Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions